These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26991354)

  • 1. Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries.
    Maciejewski ML; Hammill BG; Qualls LG; Hastings SN; Wang V; Curtis LH
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1015-22. PubMed ID: 26991354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries.
    Maciejewski ML; Mi X; Curtis LH; Ng J; Haffer SC; Hammill BG
    Circ Cardiovasc Qual Outcomes; 2016 Nov; 9(6):714-722. PubMed ID: 27756796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study.
    Schmidt M; Mansfield KE; Bhaskaran K; Nitsch D; Sørensen HT; Smeeth L; Tomlinson LA
    BMJ Open; 2017 Jan; 7(1):e012818. PubMed ID: 28069618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
    Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A
    JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study.
    Mathieson L; Severn A; Guthrie B
    Scott Med J; 2013 May; 58(2):69-76. PubMed ID: 23728750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New prescriptions of spironolactone associated with angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers and their laboratory monitoring from 2001 to 2008: a population study on older people living in the community in Italy.
    Bilotta C; Franchi C; Nobili A; Nicolini P; Djade CD; Tettamanti M; Fortino I; Bortolotti A; Merlino L; Vergani C
    Eur J Clin Pharmacol; 2013 Apr; 69(4):909-17. PubMed ID: 22996075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study.
    Sinnott SJ; Mansfield KE; Schmidt M; Bhaskaran K; Smeeth L; Nitsch D; Tomlinson LA
    BMJ Open; 2017 Nov; 7(11):e018153. PubMed ID: 29150471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Gokhale M; Girman C; Chen Y; Pate V; Funk MJ; Stürmer T
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):512-20. PubMed ID: 26860956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Management of Coronary Artery Disease in Patients With Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices.
    Figueroa JF; Blumenthal DM; Feyman Y; Frakt AB; Turchin A; Doros G; Gao Q; Song Y; Joynt Maddox KE
    JAMA Cardiol; 2019 Mar; 4(3):265-271. PubMed ID: 30785590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.
    Tisminetzky M; Gurwitz JH; Tabada G; Reynolds K; Fortmann SP; Garcia E; Pham T; Goldberg R; Go AS
    Am J Med; 2022 Dec; 135(12):1468-1477. PubMed ID: 36058306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
    Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
    Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure.
    Rathore SS; Foody JM; Wang Y; Smith GL; Herrin J; Masoudi FA; Wolfe P; Havranek EP; Ordin DL; Krumholz HM
    JAMA; 2003 May; 289(19):2517-24. PubMed ID: 12759323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Disparities in Laboratory Testing After Statin Initiation in Subjects ≥65 Years.
    Maciejewski ML; Mi X; Curtis LH; Ng J; Haffer SC; Hammill BG
    Am J Cardiol; 2016 Aug; 118(3):376-82. PubMed ID: 27289297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitors and ARBs: Managing potassium and renal function.
    Momoniat T; Ilyas D; Bhandari S
    Cleve Clin J Med; 2019 Sep; 86(9):601-607. PubMed ID: 31498767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.